去甲肾上腺素预防剖宫产腰麻后低血压的最佳输注速率:一项随机对照试验
该随机对照试验采用上下序贯分配法,在60例择期剖宫产患者中测定去甲肾上腺素与去甲肾上腺素维持产妇收缩压于基线20%以内的ED50。去甲肾上腺素ED50为1.01 µg/min(95%CI 0.84-1.18),去甲肾上腺素为12.7 µg/min(95%CI 10.5-14.9),效价比为12.6(95%CI 9.92-15.9)。作者建议预防性输注去甲肾上腺素起始速率为1.9-3.8 µg/min。
要点
- 去甲肾上腺素输注ED50为1.01 µg/min(95%CI 0.84-1.18)。
- 去甲肾上腺素与去甲肾上腺素输注效价比约12.6(95%CI 9.92-15.9)。
- 建议预防性去甲肾上腺素输注起始速率1.9-3.8 µg/min。
核心结论
- 去甲肾上腺素输注维持产妇血压的效价约为去甲肾上腺素的13倍。
- 作者推荐预防性可变速率输注去甲肾上腺素,起始1.9-3.8 µg/min。
研究设计与样本
- 随机对照试验,60例健康择期剖宫产患者,标准化腰麻,分2组。
- 采用上下序贯分配法,按Dixon-Massey公式计算ED50。
主要发现
- 去甲肾上腺素ED50为1.01 µg/min(95%CI 0.84-1.18),去甲肾上腺素为12.7 µg/min(95%CI 10.5-14.9)。
- 效价比为12.6(95%CI 9.92-15.9)。
- 两组心率、每搏量和心输出量无差异。
关键数值与推荐
- 有效性定义:维持产妇收缩压于基线20%以内。
- 剂量调整步长:去甲肾上腺素2.5 µg/min,去甲肾上腺素0.2 µg/min。
- 首例剂量:去甲肾上腺素20 µg/min,去甲肾上腺素1.6 µg/min。
临床怎么用
- 剖宫产腰麻下低血压预防可选用去甲肾上腺素输注,起始1.9-3.8 µg/min。
- 去甲肾上腺素效价约为去甲肾上腺素的13倍,换算时需注意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Norepinephrine has recently been suggested to be as effective as phenylephrine for the prevention of hypotension after spinal anesthesia for cesarean delivery. Moreover, compared to phenylephrine, norepinephrine may be superior in maintaining heart rate (HR) and consequently, cardiac output (CO). A recent study demonstrated that norepinephrine given as a single intravenous bolus is approximately 13 times more potent than phenylephrine. However, it is uncertain whether this finding can be applied when these vasopressors are administered as infusions. Therefore, the optimum infusion rate of norepinephrine remains unknown. We aimed to determine the median effective dose (ED 50 ; defined as the rate of vasopressor infusion required to prevent spinal hypotension in 50% of subjects) of both drugs needed to maintain maternal systolic blood pressure within 20% of the baseline after spinal anesthesia for cesarean delivery and to derive the relative potency ratio. METHODS: Sixty healthy patients undergoing elective cesarean delivery with standardized spinal anesthesia were randomized into 2 groups. The first patient in group 1 received phenylephrine 1200 µg in normal saline 0.9% w/v 60 mL at 60 mL/h infusion rate (20 µg.min -1 ). The first patient in group 2 received norepinephrine 96 µg in normal saline 0.9% w/v 60 mL at 60 mL/h infusion rate (1.6 µg.min -1 ). Using up-down sequential allocation technique, the vasopressor dose for every subsequent patient was determined by the response in the previous patient. If effective, the next patient received a dose reduced by 150 µg of phenylephrine (2.5 µg.min -1 ) or 12 µg (0.2 µg.min -1 ) of norepinephrine. If ineffective, the dose for the next patient was increased by the same amount. The ED50s were determined according to the Dixon-Massey formula. Stroke volume (SV), HR, and CO were also measured. RESULTS: The ED 50 was 12.7 µg.min -1 (95% CI, 10.5-14.9) for phenylephrine and 1.01 µg.min -1 (95% CI, 0.84-1.18) for norepinephrine, giving a potency ratio of 12.6 (95% CI, 9.92-15.9). HR, SV, and CO did not differ between the groups. CONCLUSIONS: Norepinephrine is more potent than phenylephrine by a factor of approximately 13 when administered as infusion for equivalent maternal blood pressure control. Based on these findings, we recommend a variable rate prophylactic infusion of norepinephrine to be initiated at 1.9 to 3.8 µg.min - 1 for the management of hypotension during cesarean delivery under spinal anesthesia.
引用
- Khatoon F, Kocarev M, Fernando R, et al. Optimal Infusion Rate of Norepinephrine for Prevention of Spinal Hypotension for Cesarean Delivery: A Randomized Controlled Trial, Using Up-Down Sequential Allocation. Anesth Analg. 2024. PMID: 39383097. doi:10.1213/ANE.0000000000007231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。